|Bid||80.05 x 100|
|Ask||81.46 x 2000|
|Day's Range||80.60 - 82.59|
|52 Week Range||28.14 - 84.37|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The development, which follows a partial clinical hold on the same product last year, raises ‘multiple concerns,’ J.P. Morgan analysts said.
Sarepta extended its lead in Duchenne muscular dystrophy on Thursday as new rival Solid Biosciences cratered after the FDA placed its trial on a clinical hold.
Shares of Sarepta Therapeutics (SRPT) are higher on Thursday, after rival Solid Biosciences' (SLDB) microdystrophin gene transfer program for Duchenne muscular dystrophy (DMD), was put on clinical hold. Solid Biosciences had to pause its IGNITE DMD clinical trial on safety concerns, after the first patient who received the gene therapy about a month ago was hospitalized due an unexpected event, including a reduced red-blood-cell count. Although the patient is recovering, Solid Biosciences reported the incident, given that it was unexpected, leading to the hold. W.C. Wainwright's Debjit Chattopadhyay reiterated a Buy rating and $92 price target on Sarepta today, writing that given the differences in the drugs and their evolving safety profiles, Solid Biosciences's setback looks like good news for Sarepta, which investors should buy "in the event of any collateral damage stemming from the Solid Biosciences clinical hold." He argues that the news will fortify the perception that Solid Biosciences' offering is a "potentially risky alternative" to Sarepta's competing investigational drug, and it may make it harder for Solid Biosciences to enroll patients in trials, especially if Sarepta continues to report positive news.
Shares of Solid Biosciences (SLDB) were hit after the FDA put a clinical hold on a phase III study of lead DMD candidate, SGT-001.
Less than two months after pulling off one of the biggest initial public offerings for a local biotech in recent years, Cambridge-based Solid Biosciences said that the FDA had halted a trial of its gene therapy treatment for Duchenne muscular dystrophy, sending shares of the company into a tailspin. Solid (SLDB) said Wednesday that the FDA had stopped an early-stage study of the drug after one patient was hospitalized due to reduced platelet and red blood cell count. "The team at Solid will be working with the principal investigator and FDA to fully understand the cause and nature of this event, as well as identify appropriate next steps as soon as possible," the company said in a statement.
The biotech sector was in focus last week with key news - Orexigen going bankrupt, Biogen acquires asset from Pfizer, Regeneron cuts Praluent price among others.
Sarepta (SRPT) will file a rolling NDA for its second DMD drug, golodirsen. The submission is expected to be completed in late 2018.
Zacks Investment Ideas feature highlights: Sarepta Therapeutics, bluebird bio, Editas Medicine, Align Technology and Intellia Therapeutics
Sarepta touched a 16-year high on the likelihood a muscular dystrophy drug could gain approval two years ahead of schedule.
Mid-caps stocks, like Sarepta Therapeutics Inc (NASDAQ:SRPT) with a market capitalization of US$4.83B, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-capRead More...
Sarepta Therapeutics, the Cambridge-based biotech that controversially won approval in 2016 for the first treatment for Duchenne muscular dystrophy, said Monday that it plans to ask the FDA later this year to approve a second drug targeting the muscle-wasting disease. Like Sarepta’s first approved drug, Exondys 51, golodirsen works by skipping over a genetic mutation that causes Duchenne muscular dystrophy in some patients. Golodirsen is designed to skip over a different sequence, exon 53, that is faulty in around 8 percent of Duchenne patients.
Shares of Sarepta Therapeutics Inc. surged 4.9% in premarket trade Monday, after the biopharmaceutical company said it planned to submit a New Drug Application (NDA) for its Duchenne muscular dystrophy ...
Sarepta Therapeutics says regulators at the Food and Drug Administration have told it they were open to reviewing its next experimental treatment for Duchenne muscular dystrophy, meaning that it could file an application for the new medicine by the end of this year.
•...examine the arguments for and against Dollar Tree. The S&P 500 is little changed at 2727.76 at 12:44 p.m. today, while the Dow Jones Industrial Average has declined 45.99 points, or 0.2%, to 24,755.37.
Sarepta (SRPT) beats earnings estimates while missing revenues in the fourth quarter of 2017, based on strong sales of Exondys 51.
On a per-share basis, the Cambridge, Massachusetts-based company said it had a loss of 37 cents. The results did not meet Wall Street expectations. The average estimate of seven analysts surveyed by Zacks ...
Sarepta Therapeutics Inc. shares dropped 1.8% after the bell on Thursday after the company reported fourth-quarter profit and revenue beats. The company reported a loss of $24 million, or a loss of 37 ...
Sarepta Therapeutics (SRPT) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.